Adverse events reported in >1% of patients receiving AccuNeb and more frequently than in patients receiving placebo in a four-week double-blind study are listed in the following table.
Table 1: Adverse Events with an Incidence of >1% of Patients Receiving AccuNeb and Greater than Placebo (expressed as % of treatment group)
|1.25 mg AccuNeb|
|0.63 mg AccuNeb|
There was one case of ST segment depression in the 1.25 mg AccuNeb treatment group.
No clinically relevant laboratory abnormalities related to AccuNeb administration were seen in this study.